tiprankstipranks
Sanofi (SNYNF)
OTHER OTC:SNYNF
US Market
SNYNF
Sanofi
RESEARCH TOOLSreports

Sanofi (SNYNF) Stock News & Sentiment

388 Followers
Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating
Premium
Ratings
Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating
6d ago
SNY
Sanofi’s Amlitelimab Eczema Trial Reaches Completion, Setting Up a Key Pipeline Catalyst
Premium
Company Announcements
Sanofi’s Amlitelimab Eczema Trial Reaches Completion, Setting Up a Key Pipeline Catalyst
26d ago
SNYNF
Sanofi’s Lunsekimig Asthma Study Completion: What Investors Should Watch Next
Premium
Company Announcements
Sanofi’s Lunsekimig Asthma Study Completion: What Investors Should Watch Next
28d ago
SNYNF
Regeneron and Sanofi Complete Key Dupilumab Pregnancy Safety Study With Fresh Data Update
Premium
Company Announcements
Regeneron and Sanofi Complete Key Dupilumab Pregnancy Safety Study With Fresh Data Update
1M ago
REGN
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial
Premium
Company Announcements
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial
2M ago
REGN
Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation
Premium
Ratings
Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation
3M ago
SNY
Is SNYNF a Buy, Before Earnings?
Premium
Pre-Earnings
Is SNYNF a Buy, Before Earnings?
3M ago
More SNYNF News >

SNYNF News on the Web

Sanofi price target raised to EUR 82 from EUR 80 at Citi
TipRanks News
Neutral
Regeneron And Sanofi's Dupixent Gets EC Approval To Treat Children Aged 2-11 Years With CSU
rttnews
Bullish
Regeneron, Sanofi announce European Commission approval for Dupixent indication
TipRanks News
Bullish
Regeneron, Sanofi Secure EU Nod To Expand Dupixent Use In Young Children With CSU
rttnews
Bullish
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sanofi (OtherSNYNF)
TipRanks News
Neutral
Sanofi becomes market authorization holder for Nuvaxovid in Canada
TipRanks News
Neutral
Dianthus initiated with an Outperform at Wolfe Research
TipRanks News
Neutral
Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
SNYNF
Sector Average
Media Buzz
This Week9 articles
Weekly Average11.5 articles
News Sentiment
This Week100%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is SNYNF’s Media Buzz Sentiment?
9 articles about SNYNF were published this week. In an average week, 11.5 articles are published.
    What is SNYNF’s weekly average amount of articles?
    In an average week, 11.5 articles about SNYNF are published.
      What is SNYNF’s News Sentiment?
      100% of articles about SNYNF were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        TXTMProText Mobility
        STAAStaar Surgical
        ALLOAllogene Therapeutics
        REPLReplimune Group
        IVVDInvivyd
        Showing the stocks with the most bullish news sentiment over the past week